Author Archives: Natalie Themm
E&I Ski Day 2025 Recap
E&I Ski Day 2025 Recap
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
First Patient Enrolled in Merit Medical’s PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
Altitude Lab Demo Day
As part of BioHive week, Altitude Lab hosted its annual Demo Day.
Steve Pacelli Appointed CEO of Epitel, Inc.
Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth
Sera Prognostics Announces Pricing of $50 Million Public Offering
Sera Prognostics Announces Pricing of $50 Million Public Offering
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
Craig-Hallum Initiates Myriad Genetics Stock with a Buy Rating
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
EVŌQ Nano Secures Strategic Investment From Global Business Leader & Philanthropist Tony Robbins to Advance Next-Generation Antimicrobial Nanoparticle Technology
